- Date
- 25 January 2021
- Time
This event has now ended
Overview
The Clinical Biomanufacturing Facility (CBF) at the University of Oxford (UK) produced the first clinical batches of the ChAdOx1 nCoV-19 vaccine against SARS-coV-2 in April 2020. In collaboration with our industrial partner AstraZeneca we have moved rapidly to get the vaccine into phase III clinical trials across the globe, and interim analysis has shown good safety and efficacy, leading to its licensure in the UK and around the world.
We developed and optimised a route to scaled up manufacture in order to produce millions of doses in the hope that it (in conjunction with other vaccines) will deliver an effective route to end the current pandemic. I will present the efforts that underpinned this highly rapid development of a vaccine against a previously unknown pathogen, the lessons that we have learnt, as well as the results generated from our early phase trials.
More like this
- Type
- Webinar
Careers talks
Aimed at students, this series of seven webinars which runs until May 2025 will enable you to learn about professional life from recent graduates from across the industry.
- Type
- Lecture
Alternative dispute resolution workshop: the role of technology and digitalisation in modern construction disputes
Join us for the ICE’s 16th Alternative Dispute Resolution workshop to discover the intricacies of adjudication in the UK. This year’s workshop will look at the role of technology and digitalisation in modern construction disputes.
- Type
- Webinar
Restoration of the 156-year-old barmouth viaduct
The presentation describes the successful integration of existing, temporary, and permanent works in the renewal of the metallic hog-back spans of the Grade II* listed Barmouth Viaduct.